July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Association Between Timing of Peak Vision Gain and Long-Term Outcomes of Ranibizumab for nAMD: A Post Hoc Analysis of HARBOR
Author Affiliations & Notes
  • Louis Chang
    Northern California Retina Vitreous Associates, Mountain View, California, United States
  • Rahul N. Khurana
    Northern California Retina Vitreous Associates, Mountain View, California, United States
  • Bann-mo Day
    Genentech, Inc, South San Francisco, California, United States
  • Avanti Ghanekar
    Genentech, Inc, South San Francisco, California, United States
  • Ivaylo Stoilov
    Genentech, Inc, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Louis Chang, Genentech, inc. (C); Rahul Khurana, Allergan (C), Genentech, Inc (C), Regeneron (C); Bann-mo Day, Genentech, Inc (E); Avanti Ghanekar, Genentech, Inc (E); Ivaylo Stoilov, Genentech, Inc (E)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 836. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Louis Chang, Rahul N. Khurana, Bann-mo Day, Avanti Ghanekar, Ivaylo Stoilov; Association Between Timing of Peak Vision Gain and Long-Term Outcomes of Ranibizumab for nAMD: A Post Hoc Analysis of HARBOR. Invest. Ophthalmol. Vis. Sci. 2018;59(9):836.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This post-hoc analysis of HARBOR (NCT00891735) identified the time of peak vision gain of patients treated with ranibizumab (RBZ), either as needed (PRN) or monthly, for neovascular age-related macular degeneration (nAMD). Magnitude of peak vision gain and 24-month (M) visual outcomes of early and late “peakers” were compared.

Methods : This retrospective analysis examined best-corrected visual acuity (BCVA) outcomes in 943 patients with nAMD from HARBOR, given RBZ monthly or PRN (0.5/2.0 mg pooled) following 3 consecutive monthly doses. Patients were grouped by time of greatest overall vision gain (peak) from baseline (BL): day (D)7–M6, M7–M12, M13–M18, and M19–M24. End points included the net gain in vision from BL to peak, and from BL to end of study (M24).

Results : Surprisingly, most patients (63.5% of PRN [n=474]; 69.7% of monthly [n=469]) reached peak vision after 6M of treatment. From BL to peak vision, patients in the PRN arm (n=474) gained a mean 12.4–22.6 ETDRS letters, with “late peakers” (ie peak achieved after M6) associated with a greater magnitude of peak vision. The mean BCVA changes from BL at M24 were –1.6, 8.5, 14.8, and 17.7 letters in D7–M6 (n=173), M7–M12 (n=100), M13–M18 (n=95), and M19–M24 (n=106) groups, respectively. This reflects a nearly 4-line difference among groups at M24, trending toward higher gains for late peakers. Importantly, similar results were observed in the monthly arm, suggesting a disease effect rather than a treatment effect. Patients achieved mean BCVA gains from BL to peak of 13.0–23.0 letters. Mean BCVA changes from BL at M24 were –1.9, 10.1, 13.5, and 18.7 letters in D7–M6 (n=142), M7–M12 (n=104), M13–M18 (n=104), and M19–M24 (n=119) groups, respectively. BL characteristics were similar among patients in all subgroups (PRN and monthly), suggesting that “peak vision” is not associated with BL characteristics.

Conclusions : The current nAMD treatment paradigm assumes it takes 3–6 injections to evaluate response to anti-VEGF treatment. Most patients in HARBOR reached peak vision after >6M of treatment, regardless of PRN or monthly dosing. The magnitude of vision gains was smaller for early vs late peakers. At M24, there was a nearly 4-line difference between the early (D7–M6) and late (M19–M24) gainers. These results suggest that vision recovery may take longer, and consistent treatment may be of long-term benefit.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×